Drug Type Biosimilar, Monoclonal antibody |
Synonyms Alemtuzumab Biosimilar (BioXpress Therapeutics SA) + [1] |
Target |
Action inhibitors |
Mechanism CD52 inhibitors(CAMPATH-1 antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Preclinical | Switzerland | 13 Mar 2024 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | Switzerland | 13 Mar 2024 |